Open AccessCoronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
Author(s) -
Foad Alzoughool,
Lo’ai Alanagreh
Publication year - 2020
Publication title -
international journal of risk and safety in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.306
H-Index - 22
eISSN - 1878-6847
pISSN - 0924-6479
DOI - 10.3233/jrs-201017
Subject(s) - covid-19 , pandemic , virology , convalescent plasma , immunization , medicine , coronavirus , antibody , immunology , disease , outbreak , infectious disease (medical specialty)
The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics.